Nepomuceno v. Duterte
REITERATIONFacts
1. The Antecedents: The underlying dispute concerns the national government's plan to procure and administer Sinovac vaccines to the Filipino populace to combat the COVID-19 pandemic. The petitioner raised concerns regarding the efficacy of the Sinovac vaccine and the absence of comprehensive studies on its performance, advocating for adherence to the Food and Drug Administration (FDA) rules on trials, procurement, and use of drugs, specifically for COVID-19 vaccines. 2. Procedural History: The case originated with a petition for a writ of mandamus filed by Pedrito Nepomuceno against various government officials, including President Rodrigo Duterte, Health Secretary Francisco Duque, and Gen. Carlito Galvez, Jr. The petition sought to compel the respondents to observe FDA rules on drug acquisition, procurement, and use, particularly concerning clinical trials and the procurement of COVID-19 vaccines like Sinovac. The Supreme Court, however, first addressed the issue of presidential immunity, ruling that President Duterte, as the incumbent President, must be dropped as a respondent due to his immunity from suit during his tenure. 3. The Petition: The petitioner filed a petition for a writ of mandamus seeking to compel respondents to adhere to FDA regulations concerning the acquisition, procurement, and use of drugs, with a specific focus on COVID-19 vaccines. The petition also prayed for the DOH FDA to issue a Cease-and-Desist Order against the purchase and use of the Sinovac vaccine and for all COVID-19 vaccines to undergo required trials in the Philippines before being approved for emergency or regular use. The Supreme Court found that the petitioner failed to identify any specific ministerial duty imposed by law on the respondents regarding clinical trials and procurement of vaccines, noting that relevant laws, such as Republic Act No. 11494 and Republic Act No. 11525, provided exemptions and discretionary powers to the executive branch in addressing the pandemic, including waiving Phase IV trial requirements and allowing negotiated procurement under emergency cases. Furthermore, the Court noted that the petition should have been filed with the regional trial court due to the doctrine of hierarchy of courts, as the issues raised involved factual considerations and were not purely legal questions of transcendental importance.
Issue(s)
Whether President Rodrigo R. Duterte is immune from suit during his tenure and must be dropped as a respondent. Whether a writ of mandamus should issue to compel the respondents to conduct clinical trials and follow standard procurement procedures for COVID-19 vaccines. Whether the petitioner's direct resort to the Supreme Court violated the doctrine of the hierarchy of courts.
Ruling
The petition is DISMISSED. 1. President Rodrigo Duterte is dropped as a respondent based on the established rule of presidential immunity from suit during his tenure. 2. The petition for a writ of mandamus is dismissed for failure to point out a ministerial duty that respondents unlawfully neglected to perform and for raising factual issues beyond the Supreme Court's original jurisdiction. 3. The Supreme Court affirmed that an incumbent President cannot be sued during their tenure, regardless of the nature of the suit. 4. The Court found no law mandating clinical trials for the procurement of COVID-19 vaccines at the time of the petition, and relevant laws like Republic Act No. 11494 (Bayanihan to Recover as One Act) and Executive Order No. 121 (EUA for COVID-19 Drugs and Vaccines) provided exemptions and granted discretion to the President and FDA in handling the pandemic response, including vaccine procurement and authorization. 5. The direct resort to the Supreme Court was deemed improper, as the issues involved questions of fact and fell within the original jurisdiction of the Regional Trial Courts, and no special or important reasons were presented to justify bypassing the doctrine of hierarchy of courts.
Ratio Decidendi
On Issue 1: The Court ruled that President Rodrigo R. Duterte must be dropped as a respondent because the President enjoys absolute immunity from suit during his tenure. Citing the En Banc ruling in De Lima v. President Duterte, the Court emphasized that this immunity applies regardless of the nature of the suit or the official or personal nature of the acts complained of. The rationale for this immunity is to allow the Chief Executive to focus entirely on the discharge of his duties without the distraction of litigation. The Court clarified that the only proceeding the President may be involved in during his term is impeachment. This immunity is understood even without an express provision in the 1987 Constitution, as it is a preserved principle in Philippine jurisprudence. On Issue 2: The Court held that mandamus is not the proper remedy because the acts sought to be compelled involve discretionary, not ministerial, duties. Under Rule 65, Section 3, mandamus lies only to compel an act which the law specifically enjoins as a duty resulting from an office. In this instance, Republic Act No. 11494 (Bayanihan to Recover as One Act) and Republic Act No. 11525 (COVID-19 Vaccination Program Act of 2021) specifically granted the President and relevant agencies the discretion to waive Phase IV clinical trials and use negotiated procurement for vaccines under Emergency Use Authorizations (EUA). Since the FDA had already issued an EUA for the Sinovac vaccine on February 22, 2021, the legal requirement for completed clinical trials was superseded by emergency legislation. Thus, there was no ministerial duty for the respondents to perform the specific acts demanded by the petitioner. On Issue 3: The Court found that the petitioner violated the doctrine of the hierarchy of courts by filing the petition directly with the Supreme Court. Although the Supreme Court shares concurrent jurisdiction with the Court of Appeals and the Regional Trial Courts (RTC) over mandamus, parties are generally required to file with the lower court first. The Court highlighted that the efficacy of a vaccine is a question of fact, and the Supreme Court is not a trier of facts. As the case required an examination of clinical trial results and comparative analyses, it should have been filed in the RTC. The petitioner failed to demonstrate any exceptional circumstances that would justify a direct resort to the highest tribunal.
Main Doctrine
An incumbent President of the Republic of the Philippines cannot be sued in any proceeding during their tenure due to presidential immunity from suit, which is absolute and applies regardless of the nature of the suit or whether the acts complained of are official or personal. Furthermore, a writ of mandamus will not issue to compel the performance of a discretionary duty, and a direct resort to the Supreme Court is improper when the issues raised are factual or when the petition fails to establish a clear legal right to the thing demanded and an imperative duty on the part of the respondent to perform the act required, especially when the matter falls within the original jurisdiction of lower courts.